Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.64 EUR 0.76% Market Closed
Market Cap: 123m EUR

Heidelberg Pharma AG
Investor Relations

Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 89 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.

Show more
Loading

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Prof. Andreas Pahl
CEO & Spokesman of the Executive Board
No Bio Available
Mr. Walter Miller
Chief Financial Officer
No Bio Available
Dr. Jorg Kemkowski
Chief Operating Officer
No Bio Available
Sylvia Wimmer
Director Corporate Communication
No Bio Available
Dr. Andras Strassz
Chief Medical Officer
No Bio Available
Dr. George Octavian Badescu
Chief Business Officer
No Bio Available

Contacts

Address
BADEN-WUERTTEMBERG
Ladenburg
Schriesheimer Strasse 101
Contacts